1. Home
  2. PTCT vs TMDX Comparison

PTCT vs TMDX Comparison

Compare PTCT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$62.76

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$129.58

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTCT
TMDX
Founded
1998
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.6B
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
PTCT
TMDX
Price
$62.76
$129.58
Analyst Decision
Buy
Buy
Analyst Count
17
9
Target Price
$79.41
$152.33
AVG Volume (30 Days)
1.0M
757.9K
Earning Date
05-12-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
264.48
382.18
EPS
7.78
4.87
Revenue
$264,734,000.00
$605,494,000.00
Revenue This Year
N/A
$24.12
Revenue Next Year
$21.65
$18.69
P/E Ratio
$8.14
$28.89
Revenue Growth
36.19
37.13
52 Week Low
$35.95
$62.42
52 Week High
$87.50
$156.00

Technical Indicators

Market Signals
Indicator
PTCT
TMDX
Relative Strength Index (RSI) 21.26 42.98
Support Level $57.74 $124.45
Resistance Level $63.19 $142.44
Average True Range (ATR) 2.77 8.65
MACD -0.57 0.04
Stochastic Oscillator 8.82 8.58

Price Performance

Historical Comparison
PTCT
TMDX

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: